Australia markets closed

SLNO Sep 2024 35.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.69000.0000 (0.00%)
As of 02:43PM EDT. Market open.
Full screen
Previous close4.6900
Open4.6900
Bid0.0000
Ask0.0000
Strike35.00
Expiry date2024-09-20
Day's range4.6900 - 4.6900
Contract rangeN/A
Volume1
Open interestN/A
  • GlobeNewswire

    Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

    REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4,

  • GlobeNewswire

    Soleno Therapeutics to Participate in Upcoming Investor Conferences

    REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare ConferenceDay: Wednesday, June 5, 2024Time:11:30 AM Eastern Time Event:Goldman Sachs 45th Annual Global Healthcare

  • GlobeNewswire

    Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

    This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome communityREDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign